Loading...
Header Logo
Keywords
Last Name
Institution

Doris M Benbrook

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentObstetrics and Gynecology
Address975 NE 10th St
Oklahoma City OK 73104-5419
Phone405/271-5523
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA077711     (BENBROOK, DORIS MANGIARACINA)Jul 1, 1999 - Jun 30, 2004
    NIH/NCI
    MECHANISM &POTENTIAL OF RETINOID &DNA DAMAGE THERAPY
    Role: Principal Investigator

    R03CA099197     (BENBROOK, DORIS MANGIARACINA)Sep 30, 2003 - Aug 31, 2006
    NIH/NCI
    Steroids and Stem Cell in Carcinogenesis
    Role: Principal Investigator

    R01CA106713     (BENBROOK, DORIS MANGIARACINA)Jun 1, 2005 - Apr 30, 2011
    NIH/NCI
    Mechanism of SHeA2 Action in Ovarian Cancer
    Role: Principal Investigator

    R01CA196200     (BENBROOK, DORIS MANGIARACINA)Jul 1, 2015 - Jun 30, 2020
    NIH/NCI
    Ovarian Cancer Chemoprevention
    Role: Principal Investigator

    N26210500038I     (Rao/Benbrook)Sep 24, 2015 - Sep 26, 2017
    NIH/NCI
    Ovarian Cancer Chemoprevention
    Role: co-Director

    R01CA200126     (BENBROOK, DORIS MANGIARACINA)Jun 1, 2016 - May 31, 2021
    NIH/NCI
    Targeting HPV Consequences in a Cervical Cancer Clinical Trial
    Role: Principal Investigator

    N26210500038I     (Rao/Benbrook)Jun 15, 2017 - Jun 14, 2019
    NIH/NCI
    Chemoprevention of Endometrial Hyperplasia and its Transition to Endometrial Cancer with SHetA2
    Role: Co-Director

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mahjabeen S, Hatipoglu MK, Chandra V, Benbrook DM, Garcia-Contreras L. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2017 Oct 06. PMID: 28989018.
      View in: PubMed
    2. Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV. Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 Sep; 152(1):36-51. PMID: 28419443.
      View in: PubMed
    3. Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 May; 145(2):291-297. PMID: 28285845.
      View in: PubMed
    4. Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390. PMID: 28260023.
      View in: PubMed
    5. Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45. PMID: 27423378.
      View in: PubMed
    6. Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S. Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. Anal Chem. 2016 Mar 15; 88(6):3130-5. PMID: 26886845.
      View in: PubMed
    7. Okon IS, Ding Y, Coughlan KA, Wang Q, Song P, Benbrook DM, Zou MH. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. 2016 Feb 16; 7(7):7970-8. PMID: 26701889; PMCID: PMC4884968.
    8. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan; 27(1):e8. PMID: 26463434; PMCID: PMC4695458.
    9. Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res. 2015; 7:291-9. PMID: 26392787; PMCID: PMC4573074.
    10. Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17. PMID: 25880346.
      View in: PubMed
    11. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43. PMID: 25019571; PMCID: PMC4278402.
    12. Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5. PMID: 24680585.
      View in: PubMed
    13. Bishop EA, Lightfoot S, Thavathiru E, Benbrook DM. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Invest. 2014 Mar; 32(3):63-70. PMID: 24499106.
      View in: PubMed
    14. Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA. History of retinoic acid receptors. Subcell Biochem. 2014; 70:1-20. PMID: 24962878.
      View in: PubMed
    15. Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Invest New Drugs. 2014 Jun; 32(3):412-23. PMID: 24254390; PMCID: PMC4045313.
    16. Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 2013 Sep; 6(9):908-16. PMID: 23852423; PMCID: PMC3769959.
    17. Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol. 2012 Oct; 34(3):286-97. PMID: 23070014.
      View in: PubMed
    18. Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, Martín-Jiménez T, Onua E, Banerjee A, van Breemen RB, Nikolic D, Chen L, Lyubimov AV. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95. PMID: 22947079.
      View in: PubMed
    19. McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61. PMID: 22796461.
      View in: PubMed
    20. Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res. 2012 Jul 04; 746(1):78-88. PMID: 22498038; PMCID: PMC3375211.
    21. Zheng J, Benbrook DM, Yu H, Ding WQ. Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Res. 2011 Sep; 31(9):2739-47. PMID: 21868515.
      View in: PubMed
    22. Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011 Dec 15; 312(1):11-7. PMID: 21899946; PMCID: PMC3395224.
    23. Dozmorov IM, Jarvis J, Saban R, Benbrook DM, Wakeland E, Aksentijevich I, Ryan J, Chiorazzi N, Guthridge JM, Drewe E, Tighe PJ, Centola M, Lefkovits I. Internal standard-based analysis of microarray data2--analysis of functional associations between HVE-genes. Nucleic Acids Res. 2011 Oct; 39(18):7881-99. PMID: 21715372; PMCID: PMC3185418.
    24. Benbrook DM, Masamha CP. The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets. 2011 Jun; 11(5):586-99. PMID: 21486222.
      View in: PubMed
    25. Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61. PMID: 21414654; PMCID: PMC3100412.
    26. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50. PMID: 20846715.
      View in: PubMed
    27. Zheng J, Lou JR, Zhang XX, Benbrook DM, Hanigan MH, Lind SE, Ding WQ. N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Lett. 2010 Dec 08; 298(2):186-94. PMID: 20667650; PMCID: PMC3881362.
    28. Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs. 2010 Mar; 21(3):297-305. PMID: 20032777; PMCID: PMC2902153.
    29. Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42. PMID: 19804900; PMCID: PMC2783732.
    30. Palwai NR, Zang XP, Harrison RG, Benbrook D, Pento JT. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5. PMID: 19797936; PMCID: PMC2834258.
    31. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009 Aug 15; 69(16):6565-72. PMID: 19638577.
      View in: PubMed
    32. Tuller ER, Beavers CT, Lou JR, Ihnat MA, Benbrook DM, Ding WQ. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Mol Pharmacol. 2009 Sep; 76(3):588-95. PMID: 19528198.
      View in: PubMed
    33. Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38. PMID: 19417155.
      View in: PubMed
    34. Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem Pharmacol. 2009 May 01; 77(9):1480-6. PMID: 19426685.
      View in: PubMed
    35. Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 Nov; 22(21):3371-81. PMID: 18837006.
      View in: PubMed
    36. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther. 2008 Nov; 7(11):3556-65. PMID: 19001438.
      View in: PubMed
    37. Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18. PMID: 18802666; PMCID: PMC2701494.
    38. Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44. PMID: 18593935.
      View in: PubMed
    39. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008 Mar 15; 68(6):1636-46. PMID: 18339842.
      View in: PubMed
    40. Benbrook DM, Lightfoot S, Ranger-Moore J, Liu T, Chengedza S, Berry WL, Dozmorov I. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul Syst Bio. 2008; 2:21-42. PMID: 19784388; PMCID: PMC2733085.
    41. Le TC, Berlin KD, Benson SD, Eastman MA, Bell-Eunice G, Nelson AC, Benbrook DM. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. Open Med Chem J. 2007 Oct 24; 1:11-23. PMID: 19662136; PMCID: PMC2709466.
    42. McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603. PMID: 17597196.
      View in: PubMed
    43. Liu T, Hannafon B, Gill L, Kelly W, Benbrook D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther. 2007 Jun; 6(6):1814-22. PMID: 17575110; PMCID: PMC2701109.
    44. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16. PMID: 17306350; PMCID: PMC1931832.
    45. Benbrook DM. Promise and problems of translational research. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S14-7. PMID: 17027066.
      View in: PubMed
    46. Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9. PMID: 16534614.
      View in: PubMed
    47. Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. Am J Pharmacol Toxicol. 2006 Jan 01; 1(4):83-86. PMID: 19890461.
      View in: PubMed
    48. Benbrook DM, Kamelle SA, Guruswamy SB, Lightfoot SA, Rutledge TL, Gould NS, Hannafon BN, Dunn ST, Berlin KD. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28. PMID: 16133793.
      View in: PubMed
    49. Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL, Benbrook DM. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecol Oncol. 2005 Apr; 97(1):142-50. PMID: 15790450.
      View in: PubMed
    50. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007. PMID: 14761202.
      View in: PubMed
    51. Brown CW, Liu S, Klucik J, Berlin KD, Brennan PJ, Kaur D, Benbrook DM. Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. J Med Chem. 2004 Feb 12; 47(4):1008-17. PMID: 14761203.
      View in: PubMed
    52. Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res. 2003 Jul 01; 63(13):3826-32. PMID: 12839980.
      View in: PubMed
    53. Mic FA, Molotkov A, Benbrook DM, Duester G. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7135-40. PMID: 12782789; PMCID: PMC165842.
    54. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002 Nov; 8(11):3520-6. PMID: 12429643.
      View in: PubMed
    55. Kamelle S, Sienko A, Benbrook DM. Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertil Steril. 2002 Sep; 78(3):596-602. PMID: 12215339.
      View in: PubMed
    56. Benbrook DM. Refining retinoids with heteroatoms. Mini Rev Med Chem. 2002 Jun; 2(3):277-83. PMID: 12370069.
      View in: PubMed
    57. Benbrook DM. An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods. 2002 May-Jun; 47(3):169-75. PMID: 12628308.
      View in: PubMed
    58. Scribner DR, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol. 2002 Apr; 85(1):223-5. PMID: 11925151.
      View in: PubMed
    Benbrook's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _